comparemela.com

Latest Breaking News On - Nasdaq aiki - Page 1 : comparemela.com

AIkido Pharma (NASDAQ:AIKI) Stock Price Crosses Above Two Hundred Day Moving Average of $2 53

AIkido Pharma Inc. (NASDAQ:AIKI – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.53 and traded as high as $2.64. AIkido Pharma shares last traded at $2.62, with a volume of 22,428 shares trading hands. AIkido Pharma Trading Down 3.1 % […]

AIkido Pharma (NASDAQ:AIKI) Stock Rating Lowered by Zacks Investment Research

AIkido Pharma (NASDAQ:AIKI – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics […]

AIkido Pharma Inc (NASDAQ:AIKI) Sees Large Decrease in Short Interest

AIkido Pharma Inc. (NASDAQ:AIKI – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 81,700 shares, a drop of 79.0% from the April 30th total of 388,300 shares. Approximately 0.1% of the company’s shares are sold short. Based […]

AIkido Pharma Inc (NASDAQ:AIKI) Short Interest Down 26 6% in April

AIkido Pharma Inc. (NASDAQ:AIKI – Get Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 388,300 shares, a decrease of 26.6% from the April 15th total of 529,300 shares. Currently, 0.4% of the shares of the stock are short […]

AIkido Pharma (NASDAQ:AIKI) Upgraded by Zacks Investment Research to Hold

AIkido Pharma (NASDAQ:AIKI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.